[211At]NaAt / Riken, Osaka University - LARVOL DELTA

First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial). (PubMed, J Nucl Med) - "Of the 5 patients who received 3.5 MBq/kg, complete response, partial response, and progressive disease were noted in 1 patient (20%) each, and SD was found in 2 patients (40%). Targeted α-therapy with [211At]NaAt was well tolerated and showed preliminary efficacy in patients with RAI-refractory DTC, supporting further clinical investigations."

First-in-human • Journal • P1 data • Dental Disorders • Hematological Disorders • Leukopenia • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Xerostomia • TG

Recent advances in theranostics and oncology PET: emerging radionuclides and targets. (PubMed, Ann Nucl Med) - "Alpha emitters, such as astatine (211At), are currently being evaluated in investigator-initiated clinical trials, with preliminary efficacy data reported for [211At]NaAt in patients with radioiodine-refractory thyroid cancer. Novel pan-tumor targeting agents, such as TROP-2, Nectin-4, LAT1, GPC-1, and EphA2, are also under development, and clinical translation of radioligand therapy is anticipated. These innovations in theranostics are expected to further broaden the scope of precision medicine in oncology."

Journal • Review • Oncology • Solid Tumor • Thyroid Gland Carcinoma • GPC1 • NECTIN4 • SSTR

Phase I investigator-initiated clinical trial of targeted alpha therapy using [211At]NaAt for refractory thyroid cancer (Alpha-T1 trial) (SNMMI 2025) - "This study demonstrated the feasibility and tolerability of targeted alpha therapy using [211At]NaAt in patients with refractory thyroid cancer. Further investigation is required in subsequent phase clinical trials to comprehensively assess its therapeutic efficacy."

Clinical • P1 data • Anorexia • Dental Disorders • Endocrine Cancer • Hematological Disorders • Leukopenia • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Xerostomia • TG